May 15, 2012 Opportunities and Challenges for Cost-Efficient Implementation of New Point-of-Care Diagnostics for HIV and Tuberculosis
May 15, 2012 Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities
May 2, 2012 Renewed Focus on Tuberculosis Holds Promise for New Treatments FDA approved rifampin for the treatment of tuberculosis (TB) in 1971, the same year Intel Corporation invented the first microproc
March 20, 2012 Critical Path Institute Honors World Tuberculosis Day 2012 Tuberculosis (TB) is often thought to be a disease of the past. The reality: Because no new therapies for TB have been developed i
November 10, 2011 CPTR Yields Progress: New Five-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Sanofi, Tibotec, TB Alli
April 30, 2011 Critical Path Institute Announces Expansion of Regulatory Science Consortium For Tuberculosis Critical Path Institute is proud to announce that the Regulatory Science Consortium, an arm of the Critical Path to TB Drug Regime
March 11, 2010 Global Partners Join Forces to Speed Development of New TB Drug Combinations FDA applauds effort to take years off development of much needed TB treatments
